Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

Circulating tumor DNA levels a few weeks after immunotherapy initiation could help identify patients with melanoma at greatest risk for recurrence or death.A retrospective analysis showed individuals ...

Emerging multiomic profiling is providing insights into the unique molecular features of brain metastases and potential targetable pathways. Molecular analysis of metastases, whenever possible, should ...

Clinical utility may be greatest with careful patient selection, given frailty-associated toxicity and potential endpoint inflation in indolent tumors, warranting larger validation cohorts and ...

Melanoma remains the most aggressive and lethal form of skin cancer, characterized by a high mutational burden and complex signaling dysregulation. Over the ...

In an interview, Vincent Ma, MD, discussed how ctDNA levels after the first cycle of immune checkpoint inhibitor in melanoma ...

Traditional FDA approval covers encorafenib plus cetuximab with fluorouracil-based chemotherapy for adult metastatic CRC with BRAF V600E mutations confirmed by an FDA-authorized test. BREAKWATER ...

Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to ...

Traditional approval was supported by BREAKWATER, a randomized, open-label phase 3 study in first-line BRAF V600E–mutant metastatic CRC comparing encorafenib/cetuximab plus chemotherapy against ...

There’s another market to look forward to this year, and this one's got a bit more going for it than your usual weekend browse. Cloud 11 and the Looker team have picked out independent creators and ...